Tana Goering, MD
Family Medicine · Wichita, KSNPI 1487616496
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Novo Nordisk at 29.8% of the total. 2025 is the largest year on record at $796, 5.8 times the $138 reported in 2019.
Across 195 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$877
- AbbVie$266
- Pfizer$240
- AstraZeneca$191
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$150
- Johnson & Johnson$133
- plus $1K from 22 others
Across 280 payments — averaging $3827.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1M
- GSK$13K
- Biohaven Pharmaceuticals, Inc.$12K
- Biohaven Pharmaceutical Holding Company Ltd.$5K
What the payments were for
- Food & beverage$2,940100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 64 | $877 |
| AbbVie | 18 | $266 |
| Pfizer | 20 | $240 |
| AstraZeneca | 11 | $191 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $150 |
| Johnson & Johnson | 10 | $133 |
| Amgen | 7 | $113 |
| GSK | 5 | $97 |
| Astellas Pharma US Inc | 6 | $97 |
| Merck | 6 | $89 |
| Eisai Inc. | 5 | $83 |
| Abbott | 4 | $74 |
| Medtronic | 2 | $67 |
| Lilly USA, LLC | 5 | $66 |
| Esperion Therapeutics, Inc. | 4 | $55 |
| Insulet Corporation | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Seqirus USA Inc | 2 | $45 |
| Bayer | 3 | $43 |
| Dexcom, Inc. | 1 | $35 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Edwards Lifesciences | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$2,940 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 46 | $48,220 |
| FarxigaDapagliflozin Propanediol | 42 | $29,051 |
| EliquisApixaban | 36 | $28,560 |
| OzempicSemaglutide | 24 | $20,755 |
| InvokanaCanagliflozin | 12 | $6,749 |
| Gabapentin | 176 | $5,251 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 101 | $4,045 |
| SynthroidLevothyroxine Sodium | 46 | $3,090 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,126 |
| Estradiol | 38 | $2,028 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 59 | $1,906 |
| Pregabalin | 47 | $1,873 |
| Levothyroxine Sodium | 255 | $1,792 |
| Atorvastatin Calcium | 392 | $1,790 |
| Omeprazole | 170 | $1,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $66 | $48,22046 claims |
| PfizerEliquis, Paxlovid | $240 | $29,98949 claims |
| AstraZenecaFarxiga | $191 | $29,05142 claims |
| Novo NordiskOzempic | $877 | $20,75524 claims |
| Johnson & JohnsonInvokana | $133 | $6,74912 claims |
| AbbVieSynthroid | $266 | $3,09046 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Wichita
- Mila MeansWichita$241K
- Cole GillenwaterWichita$62K
- Hai TruongWichita$25K
- Deborah OutwaterWichita$25K
- Joseph SackWichita$21K
- Scott StringfieldWichita$20K
- Mark LeikerWichita$20K
- Paul DavisWichita$18K
- Tara NeilWichita$16K
- William SimonWichita$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.